← Leaderboards
Rick L Tarleton
University Of Georgia
$28,594,617
Attributed
$30,185,417
Total exposure
26
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,729,398 · 27
By mechanism
R01$21,319,873 · 9
P01$11,558,587 · 6
R21$2,820,280 · 6
S10$801,696 · 2
R56$782,492 · 1
R03$446,470 · 3
Top collaborators
- Juan Bustamante2 shared
- Ronald Drew Etheridge2 shared
- Sarah Anne Hamer2 shared
- Lance Wells2 shared
- Christopher M. West2 shared
- Todd A Minning1 shared
Most similar at University Of Georgia
Same institution · by research overlap
- Lance Wells$8,888,968
- Sarah Anne Hamer$790,450
- Michael J Yabsley$444,000
Others in their field
Top investigators on “Trypanosoma Cruzi”
- Rudolf P Bohm · Tulane University Of Louisiana$19,377,842
- Robert H Gilman · Johns Hopkins University$13,384,461
- Frederick Simmons Buckner · University Of Washington$11,655,458
- Andrew E. Levin · Immunetics, Inc.$11,561,073
- Kenneth D Stuart · Seattle Children'S Hospital$11,485,507
- Nisha Jain Garg · University Of Georgia (Uga)$11,250,330
Research focus
Trypanosoma CruziChagas DiseaseInfectionParasitesImmune ResponseBaseMonitorPharmaceutical PreparationsPreventChronicVaccine DevelopmentImmuneAnimalsProteinsSiteGenesBiologyCellsPatternCommunicable DiseasesResponseDesignSuccessIn Vivo
Grant awards (94)
Treatment outcome requirements for disease prevention in Chagas disease$637,608
R01 · FY2025 · AI · contact PI
Optimization of UltraPCR for detection of and assessment of treatment outcomes in Trypanosoma cruzi infection$504,703
R01 · FY2025 · AI · contact PI
Treatment outcome requirements for disease prevention in Chagas disease$646,291
R01 · FY2024 · AI · contact PI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment$477,009
R01 · FY2024 · AI · contact PI
The activation of benzoxaborole prodrug AN15368, a clinical candidate for Chagas disease$188,750
R21 · FY2024 · AI · contact PI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment$477,009
R01 · FY2023 · AI · contact PI
The activation of benzoxaborole prodrug AN15368, a clinical candidate for Chagas disease$233,285
R21 · FY2023 · AI · contact PI
Optimizing blood PCR as test of cure in Chagas disease$75,500
R03 · FY2023 · AI · contact PI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment$477,009
R01 · FY2022 · AI · contact PI
Optimizing blood PCR as test of cure in Chagas disease$75,500
R03 · FY2022 · AI · contact PI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment$477,009
R01 · FY2021 · AI · contact PI
Multiplex treatment outcomes test for Chagas disease$998,476
R01 · FY2020 · AI · contact PI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment$477,009
R01 · FY2020 · AI · contact PI
Mechanisms of persistence in Trypanosoma cruzi infection$375,000
R01 · FY2020 · AI · contact PI
Characterizing the unique endocytic organelle of Trypanosoma cruzi$226,500
R21 · FY2020 · AI
A more effective drug treatment regimen for Trypanosoma cruzi infection$226,500
R21 · FY2020 · AI
Multiplex treatment outcomes test for Chagas disease$1,017,141
R01 · FY2019 · AI · contact PI
Mechanisms of persistence in Trypanosoma cruzi infection$375,000
R01 · FY2019 · AI · contact PI
Characterizing the unique endocytic organelle of Trypanosoma cruzi$188,542
R21 · FY2019 · AI
A more effective drug treatment regimen for Trypanosoma cruzi infection$187,917
R21 · FY2019 · AI
Multiplex treatment outcomes test for Chagas disease$1,071,447
R01 · FY2018 · AI · contact PI
Mechanisms of persistence in Trypanosoma cruzi infection$375,000
R01 · FY2018 · AI · contact PI
Multiplex treatment outcomes test for Chagas disease$1,000,819
R01 · FY2017 · AI · contact PI
Purchase of an imaging flow cytometer 2016$453,750
S10 · FY2017 · OD · contact PI
Mechanisms of persistence in Trypanosoma cruzi infection$375,000
R01 · FY2017 · AI · contact PI
Development of CRISPR/Cas system for study of trans-sialidase family genes in T. cruzi$225,000
R21 · FY2017 · AI · contact PI
Generation of reference genomes for Trypanosoma cruzi using PacBio sequencing$75,000
R03 · FY2017 · AI · contact PI
Multiplex treatment outcomes test for Chagas disease$1,127,868
R01 · FY2016 · AI · contact PI
Enabling tools for protists pathogen glycobiology$453,932
R21 · FY2016 · AI
Mechanisms of persistence in Trypanosoma cruzi infection$375,000
R01 · FY2016 · AI · contact PI
Transmission-blocking live vaccine for Chagas disease$371,250
R01 · FY2016 · AI · contact PI
Development of CRISPR/Cas system for study of trans-sialidase family genes in T. cruzi$187,500
R21 · FY2016 · AI · contact PI
Generation of reference genomes for Trypanosoma cruzi using PacBio sequencing$75,000
R03 · FY2016 · AI · contact PI
Transmission-blocking live vaccine for Chagas disease$371,250
R01 · FY2015 · AI · contact PI
Enabling tools for protists pathogen glycobiology$291,000
R21 · FY2015 · AI
Making benznidazole a better drug for Chagas disease$225,000
R21 · FY2015 · AI · contact PI
Transmission-blocking live vaccine for Chagas disease$371,250
R01 · FY2014 · AI · contact PI
Making benznidazole a better drug for Chagas disease$186,354
R21 · FY2014 · AI · contact PI
Transmission-blocking live vaccine for Chagas disease$348,975
R01 · FY2013 · AI · contact PI
Transmission-blocking live vaccine for Chagas disease$371,250
R01 · FY2012 · AI · contact PI
Immunoregulation in Experimental Chagas Disease$354,546
R01 · FY2011 · AI · contact PI
Drug Discovery Consortium for Chagas Disease$1,078,742
R01 · FY2010 · AI · contact PI
Multiplex serodiagnostic test for Chagas disease$782,492
R56 · FY2010 · AI · contact PI
Immunoregulation in Experimental Chagas Disease$358,127
R01 · FY2010 · AI · contact PI
Multi-color Flow Analyzer for the UGA-CTEGD Flow Facility$347,946
S10 · FY2010 · RR · contact PI
Drug Discovery Consortium for Chagas Disease$1,137,655
R01 · FY2009 · AI · contact PI
Immunoregulation in Experimental Chagas Disease$361,744
R01 · FY2009 · AI · contact PI
CD8+ T cell and Trypanosoma cruzi infection$342,300
R01 · FY2009 · AI · contact PI
Vaccine Discovery for Chagas Disease$1,041,153
P01 · FY2008 · AI · contact PI
Immunoregulation in Experimental Chagas Disease$361,744
R01 · FY2008 · AI · contact PI
CD8+ T cell and Trypanosoma cruzi infection$342,300
R01 · FY2008 · AI · contact PI
Gene Cloning and Testing$222,412
P01 · FY2008 · AI · contact PI
Bioinformatics$215,629
P01 · FY2008 · AI · contact PI
Prophylatic and Therapeutic Cocktail Vaccine$190,627
P01 · FY2008 · AI · contact PI
Vaccine Discovery for Chagas Disease$1,121,187
P01 · FY2007 · AI · contact PI
Immunoregulation in Experimental Chagas Disease$368,750
R01 · FY2007 · AI · contact PI
CD8+ T cell and Trypanosoma cruzi infection$348,930
R01 · FY2007 · AI · contact PI
Gene Cloning and Testing$239,510
P01 · FY2007 · AI · contact PI
Bioinformatics$232,205
P01 · FY2007 · AI · contact PI
Prophylatic and Therapeutic Cocktail Vaccine$205,279
P01 · FY2007 · AI · contact PI
Vaccine Discovery for Chagas Disease$1,072,658
P01 · FY2006 · AI · contact PI
CD8+ T cell and Trypanosoma cruzi infection$359,352
R01 · FY2006 · AI · contact PI
Immunoregulation in Experimental Chagas Disease$282,794
R01 · FY2006 · AI · contact PI
Gene Cloning and Testing$234,655
P01 · FY2006 · AI · contact PI
Bioinformatics$227,501
P01 · FY2006 · AI · contact PI
Prophylatic and Therapeutic Cocktail Vaccine$201,122
P01 · FY2006 · AI · contact PI
Microarray analysis of gene expresion in T. cruzi$71,870
R03 · FY2006 · AI · contact PI
Vaccine Discovery for Chagas Disease$1,091,483
P01 · FY2005 · AI
CD8+ T cell and Trypanosoma cruzi infection$368,000
R01 · FY2005 · AI
Immunoregulation in Experimental Chagas Disease$289,600
R01 · FY2005 · AI
Gene Cloning and Testing$233,164
P01 · FY2005 · AI
Bioinformatics$226,053
P01 · FY2005 · AI
Prophylatic and Therapeutic Cocktail Vaccine$199,841
P01 · FY2005 · AI
Microarray analysis of gene expresion in T. cruzi$73,600
R03 · FY2005 · AI
Vaccine Discovery for Chagas Disease$630,381
P01 · FY2004 · AI
Immunoregulation in Experimental Chagas Disease$289,600
R01 · FY2004 · AI
Gene Cloning and Testing$132,142
P01 · FY2004 · AI
Bioinformatics$128,112
P01 · FY2004 · AI
Prophylatic and Therapeutic Cocktail Vaccine$113,257
P01 · FY2004 · AI
VACCINE DISCOVERY FOR TRYPANOSOMA CRUZI$408,568
P01 · FY2003 · AI
Immunoregulation in Experimental Chagas Disease$289,600
R01 · FY2003 · AI
VACCINE DISCOVERY FOR TRYPANOSOMA CRUZI$710,984
P01 · FY2002 · AI
CD8+ T CELLS AND TRYPANOSOMA CRUZI INFECTIONS$342,586
R01 · FY2002 · AI
Immunoregulation in Experimental Chagas Disease$289,600
R01 · FY2002 · AI
Human immune responses to vaccine candidate antigens in chagasic patients$180,480
P01 · FY2002 · AI
Optimization of vaccine induced protection in murine Trypanozoma cruzi infection$180,480
P01 · FY2002 · AI
VACCINE DISCOVERY FOR TRYPANOSOMA CRUZI$729,701
P01 · FY2001 · AI
CD8+ T CELLS AND TRYPANOSOMA CRUZI INFECTIONS$332,608
R01 · FY2001 · AI
Human immune responses to vaccine candidate antigens in chagasic patients$180,480
P01 · FY2001 · AI
Optimization of vaccine induced protection in murine Trypanozoma cruzi infection$180,480
P01 · FY2001 · AI
VACCINE DISCOVERY FOR TRYPANOSOMA CRUZI$737,866
P01 · FY2000 · AI
CD8+ T CELLS AND TRYPANOSOMA CRUZI INFECTIONS$322,922
R01 · FY2000 · AI
Human immune responses to vaccine candidate antigens in chagasic patients$145,589
P01 · FY2000 · AI
Optimization of vaccine induced protection in murine Trypanozoma cruzi infection$145,588
P01 · FY2000 · AI